Monoclonal antibodies against calcitonin gene-related peptide for migraine prophylaxis: a systematic review of real-world data
AR Pavelic, C Wöber, F Riederer, K Zebenholzer - Cells, 2022 - mdpi.com
Objective: To perform a systematic review of real-world outcomes for anti-CGRP-mAbs.
Methods: Following the PRISMA guidelines, we searched PubMed for real-world data of …
Methods: Following the PRISMA guidelines, we searched PubMed for real-world data of …
Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review
N Vandenbussche, K Pisarek, K Paemeleire - The Journal of Headache …, 2023 - Springer
Background Real-world data are accumulating on the effectiveness, tolerability and safety of
anti-calcitonin gene-related peptide pathway monoclonal antibodies for the preventive …
anti-calcitonin gene-related peptide pathway monoclonal antibodies for the preventive …
Erenumab efficacy in migraine headache prophylaxis: A systematic review
M Bagherzadeh-Fard, MA Yazdanifar… - International …, 2023 - Elsevier
Objective This systematic review aims to show the efficiency of Erenumab in the preventive
therapy of episodic and chronic migraine, which is still under research. Background …
therapy of episodic and chronic migraine, which is still under research. Background …
Effectiveness of Calcitonin Gene-Related Peptide Monoclonal Antibodies in the Prevention of Migraine: A Systematic Review and Meta-Analysis of Observational …
Abstract Background and Objective Migraine is a neurological disorder characterized by
episodes of moderate-to-severe headache. The emergence of drugs derived from …
episodes of moderate-to-severe headache. The emergence of drugs derived from …
Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis.
J Fernández-Bravo-Rodrigo, I Cavero-Redondo… - European Journal of …, 2024 - Elsevier
Background Migraine is a common and disabling primary headache disorder. Several drugs
targeting calcitonin gene-related peptide (CGRP), such as erenumab (an anti-CGRP …
targeting calcitonin gene-related peptide (CGRP), such as erenumab (an anti-CGRP …
The effectiveness of agomelatine on headache severity and frequency in episodic migraine without aura; a parallel randomized controlled trial study
K Farzin, A Kheiltash, A Tafakhori, NE Nakhjiri… - BMC neurology, 2024 - Springer
Background Migraine is a headache disorder that affects public health and reduces the
patient's quality of life. Preventive medication is necessary to prevent acute attacks and …
patient's quality of life. Preventive medication is necessary to prevent acute attacks and …
Effectiveness of switching strategies in CGRP monoclonal antibody therapy for migraine: A retrospective cohort study
A Jaimes, A Gómez, O Pajares… - … : The Journal of Head …, 2024 - Wiley Online Library
Objective To evaluate the effectiveness of first switching between monoclonal antibodies
(mAbs) targeting calcitonin gene–related peptide (CGRP) or its receptor in the treatment of …
(mAbs) targeting calcitonin gene–related peptide (CGRP) or its receptor in the treatment of …
Prospective evaluation of aura during anti-calcitonin gene-related peptide monoclonal antibody therapy after 52 weeks of treatment
M Romozzi, A Burgalassi, C Vollono… - Confinia …, 2024 - confiniacephalalgica.com
Background: Clinical studies have shown the efficacy and safety of monoclonal antibodies
(mAbs) against calcitonin gene-related peptide (anti-CGRP) in migraine patients with and …
(mAbs) against calcitonin gene-related peptide (anti-CGRP) in migraine patients with and …